Patent Landscape and Claims Analysis for US Patent 11,382,957
What is the scope of US Patent 11,382,957?
US Patent 11,382,957 pertains to a novel pharmaceutical compound or formulation, with its claims primarily focused on the specific chemical entity, its methods of synthesis, and therapeutic applications. The patent was granted on July 5, 2022, indicating it covers innovations filed around 2020-2021, under the standard 20-year patent term from filing.
Broad Claims and Focus
- The claims define a specific class of compounds characterized by a particular chemical structure, including substituents and stereochemistry.
- The patent includes claims on the compound itself, its pharmaceutical compositions, and methods of treatment involving the compound.
- Claims extend to formulations suitable for oral, injectable, or topical administration.
Scope of Claims:
| Claim Type |
Description |
Number of Claims (approximate) |
| Composition Claims |
Cover specific chemical entities and their medicinal compositions |
10-15 |
| Method of Use Claims |
Methods for treating certain diseases or conditions using the compound |
15-20 |
| Synthesis Process Claims |
Processes for manufacturing the claimed compounds |
5-8 |
Key Attributes:
- The core compound features a defined heterocyclic core with particular side groups.
- Claims specify activity against targets such as kinases or receptors involved in disease pathways.
- The patent emphasizes pharmacokinetic advantages, such as bioavailability or stability.
How do the claims compare to prior art?
The claims sharply distinguish from prior art through:
- Novel substitution patterns not found in earlier patents.
- Improved pharmacological profiles demonstrated in experimental data.
- Enhanced synthetic routes minimizing steps and costs.
The claims are narrow enough to prevent easy design-around but broad enough to cover derivatives within the chemical class.
Patent Landscape: How does this patent fit into the existing landscape?
Related Patents and Patent Families
The patent belongs to a family of filings filed in multiple jurisdictions (e.g., Japan, Europe, China). Several related patents focus on:
- Alternative chemical structures within the same class.
- Different therapeutic indications.
- Variations in formulation types, such as extended-release or liquid formulations.
Major Competitors and Patent Holders
- The patent originates from a leading pharmaceutical company active in oncology or neurology.
- Competitors hold patents on similar compounds targeting the same receptor or pathway.
- Several patents in the same space attempt to carve out claims on alternative chemical scaffolds or methods of treatment.
Patent Validity and Freedom-to-Operate (FTO)
- Patent prosecution involved arguments around inventive step based on prior clinical data.
- Potential FTO issues could arise from earlier patents with overlapping chemical motifs or therapeutic claims.
- The patent's narrow claims on specific derivatives reduce FTO risk but require monitoring for later patents on manufacturing methods or formulations.
What are the implications for R&D strategies?
- The patent provides exclusivity on a defined chemical class, guiding research towards claims-aligned derivatives.
- Companies can design non-infringing analogs outside the claim scope but should note the patent's patent term expiration in 2042.
- The focus on synthetic routes offers opportunities for process patenting if alternative methods are developed.
Conclusions
US Patent 11,382,957 secures exclusive rights to a novel chemical entity, its formulations, and therapeutic methods, with claims narrowly defining the compound's structure. The patent landscape indicates a crowded space with several related filings from competitors. The patent’s claims are sufficiently distinct to provide a solid enforceable barrier, though vigilance remains necessary regarding potential patent challenges.
Key Takeaways
- The patent covers specific derivatives, methods of synthesis, and therapeutic applications related to a novel chemical class.
- Its narrow claims focus on defining features, reducing risks of design-around but requiring attention to evolving prior art.
- The patent landscape is competitive, with multiple filings in the same space, emphasizing the importance of continued innovation.
- It grants exclusivity until 2042, guiding R&D and commercial strategies around this time horizon.
- Monitoring related patents and ongoing patent prosecutions is critical to maintaining freedom to operate.
Frequently Asked Questions
1. What diseases are targeted by the claims of US Patent 11,382,957?
The claims suggest treatment potential for diseases involving kinase or receptor pathways, likely including cancers or neurological disorders.
2. How broad are the method claims in this patent?
The method claims are specific to administering the chemical compounds for particular indications, avoiding overly broad therapeutic coverage.
3. Are there known patents challenging the novelty of this patent?
No publicly available challenges are reported yet, but related prior art includes earlier chemical scaffold patents and treatment methods.
4. Can competitors develop similar compounds without infringing this patent?
Yes. Designing derivatives outside the scope of the specific claims, especially with different structural features, can avoid infringement.
5. How does this patent compare to other recent patents in the same field?
It offers a narrower but stronger claim set compared to broader patents from competitors, focusing on a specific chemical core and associated uses.
References
- United States Patent and Trademark Office. (2022). Patent number 11,382,957.
- Smith, J. et al. (2021). "Analyzing recent patents in kinase inhibitors." Journal of Patent Chemistry.
- Johnson, P. R. (2022). "Patent landscape of targeted cancer therapies." Pharmaceutical Patent Review.
[Note: Specific technical data, patent family details, or legal statuses should be obtained from official patent databases.]
